



**Minnesota Department of Human Services
DUR Board Meeting**

October 11, 2023

Members Present

Amanda Elliot, Pharm.D., Arnes Huskic, M.D., Daniel Jude, Pharm.D., Karen Pedersen, PharmD., and Ann Philbrick, PharmD.

DHS Staff Present

Mary Beth Reinke, PharmD., DUR Coordinator.

Other Attendants

Cory Chambliss, Kepro, and Alena Mitchell, PharmD, Kepro.

Public Comments: There were no public comments.

Approval of Minutes: The August 9, 2023, meeting minutes were approved.

Old business:

Initially approved at the May 12, 2021, DUR Board meeting, the reoccurring Psychotropics in Youth biannual mailing was sent September 11, 2023. The clinical indicator with the highest count continues to be polypsychopharmacy (3 or greater psychotropic drugs) with 599 occurrences resulting in 1,329 provider letters being mailed. Next highest, is the lack of blood glucose monitoring in patients receiving second generation antipsychotics (SGA) with 446 occurrences and lack of lipid monitoring with SGA with 361 occurrences. Attention deficit hyperactivity disorder (ADHD) high dose drug per age range was 254 occurrences. The remaining clinical indicator has less one hundred occurrences per indicator.

New business:

Drugs with Abuse Potential

The special mailing format will be used.

Inclusion criteria is all patients with a claim per “abuse potential drug” for ≥ 30 days in the last 90 days and a diagnosis of history of drug abuse and dependence within 90 days. Each abuse potential drug with their respective number of occurrences and their respective alert message is listed below:

1. Quetiapine had 273 occurrences. The alert message is Seroquel (quetiapine) should be prescribed with caution to patients with a history of substance abuse. The agent has sedative and anxiolytic properties and may be misused by some patients. Closely observe patients for signs of misuse or abuse. The use of quetiapine may put patients at risk for arrhythmias, hypotension, weight gain, and diabetes.

2. Benzodiazepines had 230 occurrences. The alert message is due to their potential for abuse, misuse, addiction, physical dependence, and withdrawal reactions, benzodiazepines should be used with caution in patients with a history of substance abuse or dependence or use disorders.
3. Opioids had 168 occurrences. The alert message is due to the potential for abuse and dependence, opioids should be used with caution in patients with a history of substance abuse or dependence, or substance use disorders.
4. Stimulants had 106 occurrences. The alert message is amphetamines are contraindicated in patients with a history of drug abuse. Chronic, abusive use can lead to tolerance, extreme psychological dependence, and severe social disability. Ramelteon is excluded.
5. Hypnotics had 77 occurrences. The alert message is due to the potential for abuse and dependence, hypnotics should be used with caution.
6. Barbiturates had one occurrence. The alert message is barbiturates should be used with caution in patients with a history of drug abuse.
7. Meprobamate didn't have any occurrences. The alert message is due to the potential for abuse and dependence, meprobamate should be used with caution.

The DUR Board approved the DUR criteria, the seven drugs with potential for abuse, and the associated alert message.

Long-Term Use of Proton Pump Inhibitors (PPIs)

Special mailing format will be used.

1. Extended Duration of PPI Therapy with No Indication for Long-Term
Criteria: PPI claim \geq 60 days within the last 120 days.
Exclusion criteria: Exclude patients with diagnosis of Zollinger-Ellison syndrome, erosive esophagitis, or Barrett's esophagitis within the last two years. Exclude patients with long term NSAID or aspirin therapy ($>$ 30 days). There were 1,543 occurrences.
2. Extended Duration of PPI Therapy in Patients with PUD without Test or Treatment for *H. pylori*
Exclusion criteria: Exclude patients with *H. pylori* testing within the last two years. Exclude patients with long term NSAID or aspirin therapy ($>$ 30 days). There were 89 occurrences.

The DUR Board approved the DUR criteria, associated message paragraphs, and the wording of each special mailing letter.

The next DUR Board meeting will be February 7, 2024. The meeting was adjourned.